CCSG Pilot: Safety and Efficacy of Cannabidiol (CBD) in Patients with Prostate Cancer with Rising PSA after Localizing Therapy with either Surgery or Radiation

Grants and Contracts Details


Prostate cancer quickly becomes resistant to androgen-ablation, the first line of therapy. Patients progress to a biochemically recurrent (BCR) state, in which PSA rises without radiological or clinical progression. This occurs many years after localized management of prostate cancer by either radical prostatectomy or radiation therapy with or without hormonal treatment. There are no clear guidelines to improve the treatment of BCR prostate cancer. However, the proposed use of CBD for these patients is not adequately justified by rigorous research on models of BCR prostate cancer cells in appropriate mouse models or in human studies.
Effective start/end date12/1/1911/30/21


  • National Cancer Institute


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.